Bristol Myers Squibb (BMY) Liabilities and Shareholders Equity (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $87.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 7.44% year-over-year to $87.6 billion in Q2 2026; TTM through Jun 2026 was $361.0 billion, a 3.3% decrease from a year earlier, with the FY2025 full-year figure at $90.0 billion, down 2.77% from the prior year.
• Liabilities and Shareholders Equity was $87.6 billion for Q2 2026 at Bristol Myers Squibb, up from $86.5 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $103.0 billion in Q1 2022 and troughed at $86.5 billion in Q1 2026.
• A 5-year average of $94.5 billion and a median of $94.5 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity slipped 11.45% in 2022 and rose 5.04% in 2024, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $96.8 billion in 2022, then dropped by 1.72% to $95.2 billion in 2023, then dropped by 2.69% to $92.6 billion in 2024, then slipped by 2.77% to $90.0 billion in 2025, then fell by 2.67% to $87.6 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $87.6 billion (Q2 2026), $86.5 billion (Q1 2026), and $90.0 billion (Q4 2025), per Business Quant data.